Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

StatusActive, Not Recruiting

PhasePhase 3

SponsorVanda Pharmaceuticals

Started2025-09-22

View on ClinicalTrials.gov ↗

Amendment history

2026-08-14

Study Status v12

Re-verified, no change to tracked fields

2026-07-17

Study Status, Contacts/Locations v11

Trial status changed: Recruiting → Active, Not Recruiting

Study sites31→30

2026-06-24

Study Status, Contacts/Locations v10

Study sites30→31

2026-05-28

Study Status, Contacts/Locations v9

Study sites29→30

2026-04-10

Study Status, Contacts/Locations v8

Study sitesdetails revised at 2 of 29 sites

Show 7 earlier versions

2026-03-12

Study Status, Contacts/Locations v7

Study sitesdetails revised at 3 of 29 sites

2026-02-25

Study Status, Contacts/Locations v6

Study sites26→29

2026-02-05

Study Status, Contacts/Locations v5

Study sites23→26

2026-01-12

Study Status, Contacts/Locations v4

Study sites20→23

2025-12-04

Study Status, Contacts/Locations v3

Study sites18→20

2025-11-10

Study Status, Contacts/Locations v2

Study sites14→18

2025-10-28

Study Status, Outcome Measures v1

Secondary endpoints3 entries, revised

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

2025-10-27

Original filing

Vanda Pharmaceuticals

23 trials monitored

See 3 trials at risk

Anxiety

2,229 trials monitored

See 91 trials at risk

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.

Trial Details

NCT Number	NCT07221578
Lead Sponsor	Vanda Pharmaceuticals
Conditions	Social Anxiety Disorder (SAD)
Enrollment	500 participants
Start Date	2025-09-22
Primary Completion	2026-12 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2026-08-17